Cargando…
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves
BACKGROUND: In Italy, the incidence of SARS-CoV-2 infection peaked in April and November 2020, defining two pandemic waves of coronavirus disease 2019 (COVID-19). This study compared the characteristics and outcomes of patients with inflammatory bowel disease (IBD) and SARS-CoV-2 infections between...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324268/ https://www.ncbi.nlm.nih.gov/pubmed/37407913 http://dx.doi.org/10.1186/s12876-023-02841-0 |
_version_ | 1785069115851931648 |
---|---|
author | Bezzio, Cristina Vernero, Marta Costa, Stefania Armuzzi, Alessandro Fiorino, Gionata Ardizzone, Sandro Roselli, Jenny Carparelli, Sonia Orlando, Ambrogio Caprioli, Flavio Andrea Castiglione, Fabiana Viganò, Chiara Ribaldone, Davide G. Zingone, Fabiana Monterubbianesi, Rita Imperatore, Nicola Festa, Stefano Daperno, Marco Scucchi, Ludovica Ferronato, Antonio Pastorelli, Luca Alimenti, Eleonora Balestrieri, Paola Ricci, Chiara Cappello, Maria Felice, Carla Coppini, Francesca Alvisi, Patrizia Di Luna, Imma Gerardi, Viviana Variola, Angela Mazzuoli, Silvia Lenti, Marco Vincenzo Saibeni, Simone |
author_facet | Bezzio, Cristina Vernero, Marta Costa, Stefania Armuzzi, Alessandro Fiorino, Gionata Ardizzone, Sandro Roselli, Jenny Carparelli, Sonia Orlando, Ambrogio Caprioli, Flavio Andrea Castiglione, Fabiana Viganò, Chiara Ribaldone, Davide G. Zingone, Fabiana Monterubbianesi, Rita Imperatore, Nicola Festa, Stefano Daperno, Marco Scucchi, Ludovica Ferronato, Antonio Pastorelli, Luca Alimenti, Eleonora Balestrieri, Paola Ricci, Chiara Cappello, Maria Felice, Carla Coppini, Francesca Alvisi, Patrizia Di Luna, Imma Gerardi, Viviana Variola, Angela Mazzuoli, Silvia Lenti, Marco Vincenzo Saibeni, Simone |
author_sort | Bezzio, Cristina |
collection | PubMed |
description | BACKGROUND: In Italy, the incidence of SARS-CoV-2 infection peaked in April and November 2020, defining two pandemic waves of coronavirus disease 2019 (COVID-19). This study compared the characteristics and outcomes of patients with inflammatory bowel disease (IBD) and SARS-CoV-2 infections between pandemic waves. METHODS: Observational longitudinal study of IBD patients with SARS-CoV-2 infection. Patients with established diagnoses of IBD and of SARS-CoV-2 infection were consecutively enrolled in two periods: (i) first wave, from 1 March 2020 to 31 May 2020; and (ii) second wave, from 15 September to 15 December 2020. RESULTS: We enrolled 937 IBD patients (219 in the first wave, 718 in the second wave). Patients of the first wave were older (mean ± SD: 46.3 ± 16.2 vs. 44.1 ± 15.4 years, p = 0.06), more likely to have ulcerative colitis (58.0% vs. 44.4%, p < 0.001) and comorbidities (48.9% vs. 38.9%; p < 0.01), and more frequently residing in Northern Italy (73.1% vs. 46.0%, p < 0.001) than patients of the second wave. There were no significant differences between pandemic waves in sex (male: 54.3% vs. 53.3%, p = 0.82) or frequency of active IBD (44.3% vs. 39.0%, p = 0.18). The rates of negative outcomes were significantly higher in the first than second wave: pneumonia (27.8% vs. 11.7%, p < 0.001), hospital admission (27.4% vs. 9.7%, p < 0.001), ventilatory support (11.9% vs. 5.4%, p < 0.003) and death (5.5% vs. 1.8%, p < 0.007). CONCLUSION: Between the first and second SARS-CoV-2 pandemic waves, demographic, clinical and geographical features of IBD patients were different as were the symptoms and outcomes of infection. These differences are likely due to the different epidemiological situations and diagnostic possibilities between the two waves. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02841-0. |
format | Online Article Text |
id | pubmed-10324268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103242682023-07-07 SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves Bezzio, Cristina Vernero, Marta Costa, Stefania Armuzzi, Alessandro Fiorino, Gionata Ardizzone, Sandro Roselli, Jenny Carparelli, Sonia Orlando, Ambrogio Caprioli, Flavio Andrea Castiglione, Fabiana Viganò, Chiara Ribaldone, Davide G. Zingone, Fabiana Monterubbianesi, Rita Imperatore, Nicola Festa, Stefano Daperno, Marco Scucchi, Ludovica Ferronato, Antonio Pastorelli, Luca Alimenti, Eleonora Balestrieri, Paola Ricci, Chiara Cappello, Maria Felice, Carla Coppini, Francesca Alvisi, Patrizia Di Luna, Imma Gerardi, Viviana Variola, Angela Mazzuoli, Silvia Lenti, Marco Vincenzo Saibeni, Simone BMC Gastroenterol Research Article BACKGROUND: In Italy, the incidence of SARS-CoV-2 infection peaked in April and November 2020, defining two pandemic waves of coronavirus disease 2019 (COVID-19). This study compared the characteristics and outcomes of patients with inflammatory bowel disease (IBD) and SARS-CoV-2 infections between pandemic waves. METHODS: Observational longitudinal study of IBD patients with SARS-CoV-2 infection. Patients with established diagnoses of IBD and of SARS-CoV-2 infection were consecutively enrolled in two periods: (i) first wave, from 1 March 2020 to 31 May 2020; and (ii) second wave, from 15 September to 15 December 2020. RESULTS: We enrolled 937 IBD patients (219 in the first wave, 718 in the second wave). Patients of the first wave were older (mean ± SD: 46.3 ± 16.2 vs. 44.1 ± 15.4 years, p = 0.06), more likely to have ulcerative colitis (58.0% vs. 44.4%, p < 0.001) and comorbidities (48.9% vs. 38.9%; p < 0.01), and more frequently residing in Northern Italy (73.1% vs. 46.0%, p < 0.001) than patients of the second wave. There were no significant differences between pandemic waves in sex (male: 54.3% vs. 53.3%, p = 0.82) or frequency of active IBD (44.3% vs. 39.0%, p = 0.18). The rates of negative outcomes were significantly higher in the first than second wave: pneumonia (27.8% vs. 11.7%, p < 0.001), hospital admission (27.4% vs. 9.7%, p < 0.001), ventilatory support (11.9% vs. 5.4%, p < 0.003) and death (5.5% vs. 1.8%, p < 0.007). CONCLUSION: Between the first and second SARS-CoV-2 pandemic waves, demographic, clinical and geographical features of IBD patients were different as were the symptoms and outcomes of infection. These differences are likely due to the different epidemiological situations and diagnostic possibilities between the two waves. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-023-02841-0. BioMed Central 2023-07-05 /pmc/articles/PMC10324268/ /pubmed/37407913 http://dx.doi.org/10.1186/s12876-023-02841-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Bezzio, Cristina Vernero, Marta Costa, Stefania Armuzzi, Alessandro Fiorino, Gionata Ardizzone, Sandro Roselli, Jenny Carparelli, Sonia Orlando, Ambrogio Caprioli, Flavio Andrea Castiglione, Fabiana Viganò, Chiara Ribaldone, Davide G. Zingone, Fabiana Monterubbianesi, Rita Imperatore, Nicola Festa, Stefano Daperno, Marco Scucchi, Ludovica Ferronato, Antonio Pastorelli, Luca Alimenti, Eleonora Balestrieri, Paola Ricci, Chiara Cappello, Maria Felice, Carla Coppini, Francesca Alvisi, Patrizia Di Luna, Imma Gerardi, Viviana Variola, Angela Mazzuoli, Silvia Lenti, Marco Vincenzo Saibeni, Simone SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves |
title | SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves |
title_full | SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves |
title_fullStr | SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves |
title_full_unstemmed | SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves |
title_short | SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves |
title_sort | sars-cov-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324268/ https://www.ncbi.nlm.nih.gov/pubmed/37407913 http://dx.doi.org/10.1186/s12876-023-02841-0 |
work_keys_str_mv | AT bezziocristina sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT verneromarta sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT costastefania sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT armuzzialessandro sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT fiorinogionata sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT ardizzonesandro sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT rosellijenny sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT carparellisonia sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT orlandoambrogio sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT caprioliflavioandrea sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT castiglionefabiana sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT viganochiara sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT ribaldonedavideg sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT zingonefabiana sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT monterubbianesirita sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT imperatorenicola sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT festastefano sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT dapernomarco sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT scucchiludovica sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT ferronatoantonio sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT pastorelliluca sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT alimentieleonora sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT balestrieripaola sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT riccichiara sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT cappellomaria sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT felicecarla sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT coppinifrancesca sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT alvisipatrizia sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT dilunaimma sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT gerardiviviana sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT variolaangela sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT mazzuolisilvia sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT lentimarcovincenzo sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT saibenisimone sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves AT sarscov2infectioninpatientswithinflammatoryboweldiseasecomparisonbetweenthefirstandsecondpandemicwaves |